



Orfadin[®] (nitisinone) – First-time generic

- On September 4, 2019, [Endo announced](#) that Par Pharmaceutical would be launching Novitium's [AB-rated](#) generic version of Swedish Orphan Biovitrum's [Orfadin \(nitisinone\)](#) capsules sometime this month.
- Orfadin is approved for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
- Orfadin is also available as a brand oral [suspension](#) that carries the same indication as Orfadin capsules.
- According to Swedish Orphan Biovitrum, global sales for Orfadin were approximately \$85 million over the last four quarters.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.